Form 4: Tactic Pharma Reduces Monopar Therapeutics Stake

Tactic Pharma LLC, a 10% owner, sold 550,229 shares of Monopar Therapeutics common stock for $63.6098 per share, reducing its beneficial ownership.

Summary

• Tactic Pharma LLC, a 10% owner of Monopar Therapeutics (MNPR), disposed of 550,229 shares of common stock.
• The transaction occurred on September 24, 2025, at a price of $63.6098 per share.
• Following this sale, Tactic Pharma LLC beneficially owns 272,026 shares of Monopar Therapeutics common stock.
• The sale was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Tactic Pharma LLC and its managers (Andrew P. Mazar, Michael J. Brown, and Thomas V. O'Halloran) are no longer subject to Section 16 reporting obligations.
• Chandler D. Robinson, Chief Executive Officer of Monopar Therapeutics and a manager of Tactic Pharma, remains subject to Section 16.

Sentiment

Score: 3

Explanation: The significant sale of shares by a 10% owner, Tactic Pharma LLC, indicates a reduction in insider confidence, although the transaction was pre-planned under a Rule 10b5-1 plan.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged sale strategy rather than an immediate reaction to market conditions.

Negatives

• A 10% owner, Tactic Pharma LLC, significantly reduced its stake in Monopar Therapeutics by selling 550,229 shares.
• The sale price of $63.6098 per share represents a substantial divestment by an insider.

Risks

• Significant reduction in ownership by a major shareholder (Tactic Pharma LLC) could be interpreted by the market as a lack of confidence in future prospects.
• The departure of Tactic Pharma LLC and several managers from Section 16 reporting obligations (except for CEO Chandler Robinson) reduces transparency regarding their future holdings and transactions.

Future Outlook

No explicit forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This Form 4 filing details an insider transaction, which is specific to the reporting entity and does not provide broader industry trends or context.

Corporate Governance

Related Party Transactions

• Tactic Pharma LLC, a 10% owner and entity associated with Monopar's CEO and other managers, sold a significant block of Monopar Therapeutics shares.

Stakeholder Impact

• Shareholders may perceive the significant insider selling as a negative signal, potentially impacting stock price.
• Reduced transparency from former 10% owners regarding their future holdings and transactions.

Key Dates

Recommendation

The significant divestment by a 10% owner, Tactic Pharma LLC, could signal reduced insider confidence. While executed under a Rule 10b5-1 plan, which suggests a pre-planned strategy, the substantial reduction in stake warrants caution. Investors should monitor future developments and company fundamentals closely.

Keywords

Monopar Therapeutics, MNPR, Tactic Pharma, insider trading, Form 4, stock sale, beneficial ownership, 10b5-1 plan